Involvement in the US criminal justice system and cost implications for persons treated for schizophrenia

BMC Psychiatry

Volumn 10, Issue , 2010, Pages

  Ascher Svanum, Haya ^a   Nyhuis, Allen W ^a   Faries, Douglas E ^a   Ball, Daniel E ^a   Kinon, Bruce J ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT;

ADULT; ARTICLE; ATTRIBUTABLE RISK; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; CRIMINAL JUSTICE; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OFFENDER; PATIENT COMPLIANCE; PROBATION; QUALITY OF LIFE INDEX; SCHIZOPHRENIA; SUBSTANCE ABUSE; TREATMENT DURATION; UNITED STATES; VICTIM; AMBULATORY CARE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST OF ILLNESS; CRIME; CRIMINAL LAW; ECONOMICS; FORENSIC PSYCHIATRY; HOSPITALIZATION; LEGAL ASPECT; MULTICENTER STUDY; PRISONER; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; STATISTICS;

ADULT; AMBULATORY CARE; ANTIPSYCHOTIC AGENTS; COMMITMENT OF MENTALLY ILL; COST OF ILLNESS; COST-BENEFIT ANALYSIS; CRIME; CRIME VICTIMS; CRIMINAL LAW; CRIMINALS; FEMALE; FORENSIC PSYCHIATRY; HEALTH CARE COSTS; HOSPITALIZATION; HUMANS; MALE; PRISONERS; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; UNITED STATES;

EID: 77951172250     PISSN: None     EISSN: 1471244X     Source Type: Journal    
DOI: 10.1186/1471-244X-10-11     Document Type: Article

References (31)

1. Morissey J, Meyer P, Cuddeback G. Extending assertive community treatment to criminal justice settings: origins, current evidence, and future directions. Community Ment Health J 2007, 43(5):527-544. 10.1007/s10597-007-9092-9, 17587178.
2. New York City Council of State Governments Justice System: Criminal Justice/Mental Health Consensus Project. , http://www.aclutx.org/files/Section%207%20--%20Prisons%20(8).pdf
3. McFarland BH, Faulkner LR, Bloom JD, Hallaux R, Bray JD. Chronic mental illness and the criminal justice system. Hosp Community Psychiatry 1989, 40(7):718-723.
4. Jacobson A, Richardson B. Assault experiences of 100 psychiatric inpatients: evidence of the need for routine inquiry. Am J Psychiatry 1987, 144(7):908-913.
5. McEvoy JP. The costs of schizophrenia. J Clin Psychiatry 2007, 68(Suppl 14):4-7.
6. Weiden PJ, Olfson M. Cost of relapse in schizophrenia. Schizophr Bull 1995, 21(3):419-429.
7. Rascati KL, Johnsrud MT, Crismon ML, Lage MJ, Barber BL. Olanzapine versus risperidone in the treatment of schizophrenia: a comparison of costs among Texas Medicaid patients. Pharmacoeconomics 2003, 21(10):683-697. 10.2165/00019053-200321100-00001, 12828491.
8. Byerly MJ, Weber M, Brooks D, Casey SB, Elliot S, Hawkins J. Cost evaluation of risperidone compared with olanzapine. Psychiatr Serv 2003, 54(5):742-744. 10.1176/appi.ps.54.5.742, 12719509.
9. Stargardt T, Weinbrenner S, Busse R, Juckel G, Gericke CA. Effectiveness and cost of atypical versus typical antipsychotic treatment for schizophrenia in routine care. J Ment Health Policy Econ 2008, 11(2):89-97.
10. Knapp M, Mangalore R, Simon J. The global costs of schizophrenia. Schizophr Bull 2004, 30(2):279-293.
11. Mangalore R, Knapp M. Cost of schizophrenia in England. J Ment Health Policy Econ 2007, 10(1):23-41.
12. Wu EQ, Birnbaum HG, Shi L, Ball DE, Kessler RC, Moulis M, Aggarwal J. The economic burden of schizophrenia in the United States in 2002. J Clin Psychiatry 2005, 66(9):1122-1129. 10.4088/JCP.v66n0906, 16187769.
13. Tunis SL, Faries DE, Nyhuis AW, Kinon BJ, Ascher-Svanum H, Aquila R. Cost-effectiveness of olanzapine as first-line treatment for schizophrenia: results from a randomized, open-label, 1-year trial. Value Health 2006, 9(2):77-89. 10.1111/j.1524-4733.2006.00083.x, 16626411.
14. Overall JE, Gorham DR. The brief psychiatric rating scale. Psychol Rep 1962, 10:799-812.
15. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987, 13(2):261-276.
16. Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992, 30(6):473-483. 10.1097/00005650-199206000-00002, 1593914.
17. Valenstein M, Copeland LA, Blow FC, McCarthy JF, Zeber JE, Gillon L, Bingham CR, Stavenger T. Pharmacy data identify poorly adherent patients with schizophrenia at increased risk for admission. Med Care 2002, 40(8):630-639. 10.1097/00005650-200208000-00002, 12187177.
18. Lehman AF, Steinwachs DM. Patterns of usual care for schizophrenia: initial results from the Schizophrenia Patient Outcomes Research Team (PORT) Client Survey. Schizophr Bull 1998, 24(1):11-20.
19. Lehman AF. A quality of life interview for the chronically mentally ill. Eval Program Plann 1988, 11(1):51-62.
20. Clark RE, Ricketts SK, McHugo GJ. Legal system involvement and costs for persons in treatment for severe mental illness and substance use disorders. Psychiatr Serv 1999, 50(5):641-647.
21. Administrative Office of the US Courts: FY 2004 Costs of Incarceration and Supervision. , http://www.uscourts.gov/ttb/may05ttb/incarceration-costs/index.html
22. Ascher-Svanum H, Faries DE, Zhu B, Ernst FR, Swartz MS, Swanson JW. Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care. J Clin Psychiatry 2006, 67(3):453-460. 10.4088/JCP.v67n0317, 16649833.
23. Swanson JW, Swartz MS, Van Dorn RA, Volavka J, Monahan J, Stroup TS, McEvoy JP, Wagner HR, Elbogen EB, Lieberman JA, . CATIE investigators Comparison of antipsychotic medication effects on reducing violence in people with schizophrenia. Br J Psychiatry 2008, 193(1):37-43. 10.1192/bjp.bp.107.042630, 18700216, CATIE investigators.
24. Swanson JW, Swartz MS, Elbogen EB, Van Dorn RA. Reducing violence risk in persons with schizophrenia: olanzapine versus risperidone. J Clin Psychiatry 2004, 65(12):1666-1673.
25. Swanson JW, Swartz MS, Elbogen EB. Effectiveness of atypical antipsychotic medications in reducing violent behavior among persons with schizophrenia in community-based treatment. Schizophr Bull 2004, 30(1):3-20.
26. Theriot MT, Segal SP. Involvement with the criminal justice system among new clients at outpatient mental health agencies. Psychiatr Serv 2005, 56(2):179-185. 10.1176/appi.ps.56.2.179, 15703345.
27. Swartz MS, Swanson JW, Hiday VA, Borum R, Wagner R, Burns BJ. Taking the wrong drugs: the role of substance abuse and medication noncompliance in violence among severely mentally ill individuals. Soc Psychiatry Psychiatr Epidemiol 1998, 33(Suppl 1):S75-S80. 10.1007/s001270050213, 9857783.
28. Baillargeon J, Binswanger IA, Penn JV, Williams BA, Murray OJ. Psychiatric disorders and repeat incarcerations: the revolving prison door. Am J Psychiatry 2009, 166(1):103-109. 10.1176/appi.ajp.2008.08030416, 19047321.
29. Swanson JW, Swartz MS, Van Dorn RA, Elbogen EB, Wagner HR, Rosenheck RA, Stroup TS, McEvoy JP, Lieberman JA. A national study of violent behavior in persons with schizophrenia. Arch Gen Psychiatry 2006, 63(5):490-499. 10.1001/archpsyc.63.5.490, 16651506.
30. Hiday VA, Swartz MS, Swanson JW, Borum R, Wagner HR. Criminal victimization of persons with severe mental illness. Psychiatr Serv 1999, 50:62-68.
31. Lehman AF, Linn LS. Crimes against discharged mental patients in board-and-care homes. Am J Psychiatry 1984, 141:271-274.